JP2007520540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520540A5 JP2007520540A5 JP2006551923A JP2006551923A JP2007520540A5 JP 2007520540 A5 JP2007520540 A5 JP 2007520540A5 JP 2006551923 A JP2006551923 A JP 2006551923A JP 2006551923 A JP2006551923 A JP 2006551923A JP 2007520540 A5 JP2007520540 A5 JP 2007520540A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidin
- thiazol
- chloro
- compound
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 12
- -1 4-methylthiazol-2-yl Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108090000433 Aurora kinases Proteins 0.000 claims 2
- 102000003989 Aurora kinases Human genes 0.000 claims 2
- 108091007911 GSKs Proteins 0.000 claims 2
- 102000038624 GSKs Human genes 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- ZYAAOFFRIZSHKG-UHFFFAOYSA-N ethyl 2-[2-(4-chloroanilino)pyrimidin-4-yl]-4-hydroxy-1,3-thiazole-5-carboxylate Chemical compound OC1=C(C(=O)OCC)SC(C=2N=C(NC=3C=CC(Cl)=CC=3)N=CC=2)=N1 ZYAAOFFRIZSHKG-UHFFFAOYSA-N 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- DFKBWWLQZWPHAU-UHFFFAOYSA-N n-(6-methoxypyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C=2SC=CN=2)=N1 DFKBWWLQZWPHAU-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- AMEYMCDOKAYHNU-UHFFFAOYSA-N 2-[2-[(6-chloropyridin-3-yl)amino]pyrimidin-4-yl]-5-methyl-1,3-thiazol-4-ol Chemical compound OC1=C(C)SC(C=2N=C(NC=3C=NC(Cl)=CC=3)N=CC=2)=N1 AMEYMCDOKAYHNU-UHFFFAOYSA-N 0.000 claims 1
- LPMPZSLQZGKCCU-UHFFFAOYSA-N 3-n-[4-(4,5-dimethyl-1,3-thiazol-2-yl)pyrimidin-2-yl]benzene-1,3-diamine Chemical compound S1C(C)=C(C)N=C1C1=CC=NC(NC=2C=C(N)C=CC=2)=N1 LPMPZSLQZGKCCU-UHFFFAOYSA-N 0.000 claims 1
- FEQQALGLKRLIPK-UHFFFAOYSA-N 4-(4,5-dimethyl-1,3-thiazol-2-yl)-n-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C=2SC(C)=C(C)N=2)=C1 FEQQALGLKRLIPK-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- HOPVZZZPBBETCV-UHFFFAOYSA-N C(C)OC(=O)C1=C(N=C(S1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C1=CC=CC=C1 Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C1=CC=CC=C1 HOPVZZZPBBETCV-UHFFFAOYSA-N 0.000 claims 1
- FTQIYEJGQVOMJL-UHFFFAOYSA-N CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C Chemical compound CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C FTQIYEJGQVOMJL-UHFFFAOYSA-N 0.000 claims 1
- CHEHWXHOTMAJOR-UHFFFAOYSA-N CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)O.CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC(=C(C=C1)C)[N+](=O)[O-] Chemical compound CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)O.CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC(=C(C=C1)C)[N+](=O)[O-] CHEHWXHOTMAJOR-UHFFFAOYSA-N 0.000 claims 1
- GTYAEYNUFDCEFV-UHFFFAOYSA-N CC=1N=C(SC1C)C1=NC(=NC=C1)NC=1C=NC(=CC1)OC.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O Chemical compound CC=1N=C(SC1C)C1=NC(=NC=C1)NC=1C=NC(=CC1)OC.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O GTYAEYNUFDCEFV-UHFFFAOYSA-N 0.000 claims 1
- UMQAAJLCTFZUGO-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)O)C(=O)O.COC(CC=1N=C(SC1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)=O Chemical compound ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)O)C(=O)O.COC(CC=1N=C(SC1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)=O UMQAAJLCTFZUGO-UHFFFAOYSA-N 0.000 claims 1
- QZSNMAAZRPQZGJ-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O Chemical compound ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O QZSNMAAZRPQZGJ-UHFFFAOYSA-N 0.000 claims 1
- DRFUEMRXRKKVTE-UHFFFAOYSA-N ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.COC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1 Chemical compound ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.COC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1 DRFUEMRXRKKVTE-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 102000001267 GSK3 Human genes 0.000 claims 1
- 108060006662 GSK3 Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 claims 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- AFOGVURHRPHMFJ-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4,5-dimethyl-1,3-thiazol-2-yl)pyrimidin-2-amine 4-(4,5-dimethyl-1,3-thiazol-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C)C(F)(F)F.CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC(=CC=C1)C(F)(F)F AFOGVURHRPHMFJ-UHFFFAOYSA-N 0.000 claims 1
- DUILLRPTPDOWDS-UHFFFAOYSA-N N1(CCCC1)C1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.ClC1=CC=C(C=C1)NC1=NC=CC(=C1)C=1SC(=C(N1)O)C Chemical compound N1(CCCC1)C1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.ClC1=CC=C(C=C1)NC1=NC=CC(=C1)C=1SC(=C(N1)O)C DUILLRPTPDOWDS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- ZULPZVQQKCPAAS-UHFFFAOYSA-N n-(6-chloro-5-methylpyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound N1=C(Cl)C(C)=CC(NC=2N=C(C=CN=2)C=2SC=CN=2)=C1 ZULPZVQQKCPAAS-UHFFFAOYSA-N 0.000 claims 1
- LNTKBKLVTCCBCH-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound C1=NC(Cl)=CC=C1NC1=NC=CC(C=2SC=CN=2)=N1 LNTKBKLVTCCBCH-UHFFFAOYSA-N 0.000 claims 1
- BWPWWOIILUWVKU-UHFFFAOYSA-N n-(6-pyrrolidin-1-ylpyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound C1CCCN1C(N=C1)=CC=C1NC1=NC=CC(C=2SC=CN=2)=N1 BWPWWOIILUWVKU-UHFFFAOYSA-N 0.000 claims 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402653.0A GB0402653D0 (en) | 2004-02-06 | 2004-02-06 | Compounds |
| PCT/GB2005/000405 WO2005075468A2 (en) | 2004-02-06 | 2005-02-07 | Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520540A JP2007520540A (ja) | 2007-07-26 |
| JP2007520540A5 true JP2007520540A5 (enExample) | 2008-02-28 |
Family
ID=31985793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551923A Pending JP2007520540A (ja) | 2004-02-06 | 2005-02-07 | 化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080318954A1 (enExample) |
| EP (1) | EP1751146B1 (enExample) |
| JP (1) | JP2007520540A (enExample) |
| CN (1) | CN1914199A (enExample) |
| AT (1) | ATE450532T1 (enExample) |
| AU (1) | AU2005210254A1 (enExample) |
| BR (1) | BRPI0507506A (enExample) |
| CA (1) | CA2554329A1 (enExample) |
| DE (1) | DE602005018044D1 (enExample) |
| GB (1) | GB0402653D0 (enExample) |
| IL (1) | IL177252A0 (enExample) |
| WO (1) | WO2005075468A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| JP4886511B2 (ja) | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
| AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| TW200734327A (en) * | 2005-11-03 | 2007-09-16 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
| NZ580454A (en) * | 2007-03-16 | 2011-05-27 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
| TW200920355A (en) | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
| WO2009103032A1 (en) | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| AP3272A (en) | 2008-09-22 | 2015-05-31 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases |
| US20110112158A1 (en) | 2009-11-11 | 2011-05-12 | David Robert Bolin | Benzisoxazole analogs as glycogen synthase activators |
| US7947728B1 (en) | 2009-11-11 | 2011-05-24 | Hoffmann-La Roche Inc. | Indole and indazole analogs as glycogen synthase activators |
| US20110112147A1 (en) | 2009-11-11 | 2011-05-12 | David Robert Bolin | Indazolone analogs as glycogen synthase activators |
| US8039495B2 (en) | 2009-11-16 | 2011-10-18 | Hoffman-La Roche Inc. | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators |
| US20110118314A1 (en) | 2009-11-16 | 2011-05-19 | Weiya Yun | Piperidine analogs as glycogen synthase activators |
| US7939569B1 (en) | 2009-12-01 | 2011-05-10 | Hoffmann-La Roche Inc. | Aniline analogs as glycogen synthase activators |
| US20110136792A1 (en) | 2009-12-04 | 2011-06-09 | David Robert Bolin | Novel carboxylic acid analogs as glycogen synthase activators |
| HUE029196T2 (en) | 2010-06-04 | 2017-02-28 | Hoffmann La Roche | Aminoprimidine derivatives as LRRK2 modulators |
| SG189043A1 (en) | 2010-11-10 | 2013-05-31 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| US9242976B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| EP2802577B1 (en) | 2012-01-13 | 2017-03-01 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| WO2013106612A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| PE20150953A1 (es) | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa |
| ES2616812T3 (es) | 2012-11-08 | 2017-06-14 | Bristol-Myers Squibb Company | Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| JP2017508772A (ja) | 2014-03-24 | 2017-03-30 | エービー サイエンス | 脾臓チロシンキナーゼ阻害剤としてのジアザスピロアルカノン置換型オキサゾール誘導体 |
| UY36747A (es) | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen |
| US10618903B2 (en) | 2015-06-24 | 2020-04-14 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| AR105113A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| EP3957637B1 (en) * | 2015-08-04 | 2023-06-28 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
| EP3144307A1 (en) | 2015-09-18 | 2017-03-22 | AB Science | Novel oxazole derivatives that inhibit syk |
| MY200228A (en) | 2017-05-11 | 2023-12-15 | Bristol Myers Squibb Co | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| WO2021011727A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS |
| JP7573596B2 (ja) | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| CN114174279B (zh) | 2019-08-06 | 2024-07-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的双环杂环化合物 |
| US12570659B2 (en) | 2019-08-13 | 2026-03-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds useful as IRAK4 inhibitors |
| CN115335380B (zh) | 2020-02-03 | 2024-08-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的三环杂芳基化合物 |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| CN115484952B (zh) * | 2020-03-27 | 2024-10-18 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| PL313973A1 (en) * | 1993-10-12 | 1996-08-05 | Du Pont Merck Pharma | 1 n-alkyl-n-arylopyrimidin amines and their derivatives |
| GB9519275D0 (en) * | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| WO1997042222A1 (en) * | 1996-05-08 | 1997-11-13 | Cyclacel Limited | Methods and means for inhibition of cdk4 activity |
| US6703395B2 (en) * | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US6221873B1 (en) * | 1998-03-04 | 2001-04-24 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| CN1312807A (zh) * | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| JP4523271B2 (ja) * | 2001-06-01 | 2010-08-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール化合物 |
| EP1430051B1 (en) * | 2001-09-28 | 2006-12-27 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds |
| WO2004005283A1 (en) * | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| DE602004014117D1 (de) * | 2003-03-25 | 2008-07-10 | Vertex Pharma | Thiazole zur verwendung als inhibitoren von protein-kinasen |
| EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| AU2004261482A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
| JP5164380B2 (ja) * | 2003-10-21 | 2013-03-21 | サイクラセル リミテッド | ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用 |
-
2004
- 2004-02-06 GB GBGB0402653.0A patent/GB0402653D0/en not_active Ceased
-
2005
- 2005-02-07 AU AU2005210254A patent/AU2005210254A1/en not_active Abandoned
- 2005-02-07 JP JP2006551923A patent/JP2007520540A/ja active Pending
- 2005-02-07 DE DE602005018044T patent/DE602005018044D1/de not_active Expired - Fee Related
- 2005-02-07 CN CNA2005800039602A patent/CN1914199A/zh active Pending
- 2005-02-07 AT AT05702134T patent/ATE450532T1/de not_active IP Right Cessation
- 2005-02-07 WO PCT/GB2005/000405 patent/WO2005075468A2/en not_active Ceased
- 2005-02-07 EP EP05702134A patent/EP1751146B1/en not_active Expired - Lifetime
- 2005-02-07 CA CA002554329A patent/CA2554329A1/en not_active Abandoned
- 2005-02-07 US US10/588,372 patent/US20080318954A1/en not_active Abandoned
- 2005-02-07 BR BRPI0507506-8A patent/BRPI0507506A/pt not_active IP Right Cessation
-
2006
- 2006-08-02 IL IL177252A patent/IL177252A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520540A5 (enExample) | ||
| JP2007509117A5 (enExample) | ||
| JP2008500320A5 (enExample) | ||
| JP2007500178A5 (enExample) | ||
| US10590094B2 (en) | Aminothiazole derivatives useful as antiviral agents | |
| AU2001242629B2 (en) | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders | |
| US20110092490A1 (en) | Pyrimidines, triazines and their use as pharmaceutical agents | |
| US7902361B2 (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
| US8329916B2 (en) | Human protein tyrosine phosphatase inhibitors and method of use | |
| JP2007500179A5 (enExample) | ||
| DE60217140T2 (de) | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen | |
| US20060241297A1 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
| RU2469036C2 (ru) | Имидазопиридиновые ингибиторы киназ | |
| US11278534B2 (en) | Enantiomers of substituted thiazoles as antiviral compounds | |
| US20050288307A1 (en) | Anti-viral compounds | |
| US20090137572A1 (en) | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
| JP2011526616A5 (enExample) | ||
| US20030208067A1 (en) | Inhibitors of protein kinase for the treatment of disease | |
| AU2004261484A1 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
| JP2004515550A5 (enExample) | ||
| HUP0201122A2 (en) | Pyrimidinone compounds, process for their preparation and pharmaceutical compositions containing them | |
| JP2008526824A5 (enExample) | ||
| JP2014528450A5 (enExample) | ||
| CA2450934A1 (en) | Pyrimidine inhibitors of phosphodiesterase (pde) 7 | |
| CN1592743A (zh) | 糖元合成酶激酶3的抑制剂 |